BG107266A - Кристална форма на терапевтично средство - Google Patents

Кристална форма на терапевтично средство Download PDF

Info

Publication number
BG107266A
BG107266A BG107266A BG10726602A BG107266A BG 107266 A BG107266 A BG 107266A BG 107266 A BG107266 A BG 107266A BG 10726602 A BG10726602 A BG 10726602A BG 107266 A BG107266 A BG 107266A
Authority
BG
Bulgaria
Prior art keywords
ethyl
compound
ethoxy
mol
mixture
Prior art date
Application number
BG107266A
Other languages
Bulgarian (bg)
English (en)
Inventor
Laurence HARRIS
Richard Storey
Albert Wood
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG107266A publication Critical patent/BG107266A/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
BG107266A 2000-07-28 2002-11-12 Кристална форма на терапевтично средство BG107266A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent
PCT/IB2001/001280 WO2002010171A1 (en) 2000-07-28 2001-07-18 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
BG107266A true BG107266A (bg) 2003-07-31

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107266A BG107266A (bg) 2000-07-28 2002-11-12 Кристална форма на терапевтично средство

Country Status (46)

Country Link
EP (1) EP1305314B1 (es)
JP (1) JP2004505087A (es)
KR (1) KR100457937B1 (es)
CN (1) CN1207297C (es)
AP (1) AP1400A (es)
AR (1) AR032628A1 (es)
AT (1) ATE286901T1 (es)
AU (2) AU2001272690B2 (es)
BG (1) BG107266A (es)
BR (1) BR0112734A (es)
CA (1) CA2417264C (es)
CZ (1) CZ2003126A3 (es)
DE (1) DE60108398T2 (es)
DO (1) DOP2001000217A (es)
DZ (1) DZ3364A1 (es)
EA (1) EA004681B1 (es)
EC (1) ECSP034454A (es)
EE (1) EE200300045A (es)
ES (1) ES2231521T3 (es)
GE (1) GEP20053494B (es)
HK (1) HK1055954A1 (es)
HR (1) HRP20030061A2 (es)
HU (1) HUP0302982A3 (es)
IL (1) IL153226A0 (es)
IN (1) IN2002MU01649A (es)
IS (1) IS6626A (es)
MA (1) MA26931A1 (es)
MX (1) MX233602B (es)
MY (1) MY117831A (es)
NO (1) NO324220B1 (es)
NZ (1) NZ523226A (es)
OA (1) OA12337A (es)
PA (1) PA8523501A1 (es)
PE (1) PE20020277A1 (es)
PH (1) PH12001001922B1 (es)
PL (1) PL365133A1 (es)
PT (1) PT1305314E (es)
SK (1) SK572003A3 (es)
SV (1) SV2001000570A (es)
TN (1) TNSN01112A1 (es)
TW (1) TWI285643B (es)
UA (1) UA72631C2 (es)
UY (1) UY26854A1 (es)
WO (1) WO2002010171A1 (es)
YU (1) YU4703A (es)
ZA (1) ZA200301457B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
EP1620437B1 (en) 2003-04-29 2009-06-17 Pfizer Limited 5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
ATE417849T1 (de) 2004-04-07 2009-01-15 Pfizer Pyrazoloä4,3-düpyrimidine
KR100939890B1 (ko) 2005-05-12 2010-01-29 화이자 인코포레이티드 N-[1-(2-에톡시에틸)-5-(N-에틸-N-메틸아미노)-7-(4-메틸피리딘-2-일-아미노)-1H-피라졸로[4,3-d]피리미딘-3-카르보닐]메탄술폰아미드의 무수 결정 형태

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1134442C (zh) * 1998-04-20 2004-01-14 美国辉瑞有限公司 吡唑并嘧啶酮cGMP PDE5抑制剂、其制备方法及用途及中间体
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
AP2001002234A0 (en) 2001-09-30
MA26931A1 (fr) 2004-12-20
BR0112734A (pt) 2004-08-10
DE60108398D1 (de) 2005-02-17
KR20030016430A (ko) 2003-02-26
PA8523501A1 (es) 2002-10-24
AP1400A (en) 2005-04-28
HUP0302982A2 (hu) 2003-12-29
IL153226A0 (en) 2003-07-06
CN1207297C (zh) 2005-06-22
EP1305314A1 (en) 2003-05-02
SK572003A3 (en) 2004-05-04
EA200300079A1 (ru) 2003-06-26
MXPA03000856A (es) 2003-06-06
CA2417264C (en) 2007-06-12
EP1305314B1 (en) 2005-01-12
SV2001000570A (es) 2002-09-03
MY117831A (en) 2004-08-30
HUP0302982A3 (en) 2005-01-28
MX233602B (es) 2006-01-10
NO20030416L (no) 2003-02-05
JP2004505087A (ja) 2004-02-19
UA72631C2 (uk) 2005-03-15
CA2417264A1 (en) 2002-02-07
HRP20030061A2 (en) 2003-04-30
CZ2003126A3 (cs) 2004-02-18
AU7269001A (en) 2002-02-13
NO20030416D0 (no) 2003-01-27
ATE286901T1 (de) 2005-01-15
AR032628A1 (es) 2003-11-19
PT1305314E (pt) 2005-04-29
PE20020277A1 (es) 2002-05-11
DZ3364A1 (fr) 2002-02-07
OA12337A (en) 2006-05-15
AU2001272690B2 (en) 2005-12-08
ZA200301457B (en) 2004-04-28
NO324220B1 (no) 2007-09-10
PL365133A1 (en) 2004-12-27
IS6626A (is) 2002-11-18
ES2231521T3 (es) 2005-05-16
UY26854A1 (es) 2002-02-28
EA004681B1 (ru) 2004-06-24
TWI285643B (en) 2007-08-21
KR100457937B1 (ko) 2004-11-20
CN1444585A (zh) 2003-09-24
TNSN01112A1 (fr) 2005-11-10
DE60108398T2 (de) 2005-12-22
GEP20053494B (en) 2005-04-25
IN2002MU01649A (es) 2004-12-11
NZ523226A (en) 2003-07-25
DOP2001000217A (es) 2002-10-30
PH12001001922B1 (en) 2006-11-21
HK1055954A1 (en) 2004-01-30
ECSP034454A (es) 2003-03-10
EE200300045A (et) 2004-12-15
WO2002010171A1 (en) 2002-02-07
YU4703A (sh) 2006-01-16

Similar Documents

Publication Publication Date Title
KR100549152B1 (ko) 피라졸로[4,3-d]피리미딘 유도체
MXPA06000484A (es) Sal de isetionato de un inhibidor selectivo de la quinasa 4 dependiente de ciclina.
US9902698B2 (en) 2-[[[2-[(Hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzenesulfonate, crystal of same, crystal polymorph thereof, and methods for production thereof
ES2331487T3 (es) Forma cristalina estable de bifeprunox mesilato, formas de dosificacion del mismo y metodos de utilizacion.
BG107266A (bg) Кристална форма на терапевтично средство
US6420557B1 (en) Crystalline therapeutic agent
US6350751B1 (en) Therapeutic agents
AU2001272690A1 (en) Crystalline therapeutic agent
ES2219395T3 (es) Sal anhidra.
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида